Cargando…
An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries
BACKGROUND: chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as one of the most distressing adverse effects among treated patients with cancer. Inadequately treated, CINV can lead to increased resource utilization and severely impair patients’ daily functioning and quality...
Autores principales: | Turini, Marco, Piovesana, Vittoria, Ruffo, Pierfrancesco, Ripellino, Claudio, Cataldo, Nazarena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544273/ https://www.ncbi.nlm.nih.gov/pubmed/26322114 http://dx.doi.org/10.7573/dic.212285 |
Ejemplares similares
-
Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey
por: Aapro, Matti, et al.
Publicado: (2018) -
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022) -
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017) -
Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015) -
Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)